Sleep and Light Intervention (SALI) for Menopausal Mood Dysfunction
This study is looking at how changes in sleep timing and light exposure might help improve mood and sleep problems during menopause. Researchers want to see if resetting your body's internal clock (circadian rhythm) can help with depression symptoms. You would either adjust your sleep to an earlier time (9 PM to 1 AM) for one night, followed by 30 minutes of bright white light in the morning for two weeks, or adjust your sleep to a later time (3 AM to 7 AM) for one night, followed by 30 minutes of bright white light in the evening for two weeks. The study will measure melatonin levels in your urine and use questionnaires to track changes in your mood and depression symptoms. This study is for women over 18 who are going through perimenopause (irregular periods) and have moderate depression.
- Study design
- This interventional study plans to enroll 120 women. Participants will be assigned to one of two behavioral interventions: Phase Advanced Intervention or Phase Delay Intervention.
- What's involved
- You will provide urine samples, adjust your sleep for one night, and use a bright light box for 30 minutes daily for two weeks. You will also complete questionnaires at different times.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your mood and depression symptoms will be tracked for two weeks after the intervention and then again for up to three months after the intervention ends.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Sleep and Light Intervention (SALI) for Menopausal Mood Dysfunction
At a glance
Conditions
NCT06678880
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
University of California San Diego Hillcrest Medical Center
San Diego, Californiastudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Barbara Parry, M.D. · PRINCIPAL_INVESTIGATOR · University of California, San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Urinary 6-sulfatoxymelatonin (6-SMT)Urine is collected at baseline and after completing two-week intervention.
Collected to measure melatonin, a hormone that helps regulate your sleep and body clocks.
- Structured Interview Guide for the Hamilton Rating Depression Scale with Atypical Depression Supplement (SIGH-ADS)Completed at baseline and after completing two-week intervention.
A clinician-conducted interview that asks about symptoms of depression, including mood, sleep, appetite, energy, and other emotional and physical symptoms.
- Patient Health Questionnaire (PHQ-9)Completed at baseline and after completing two-week intervention.
A brief questionnaire that asks about common symptoms of depression, such as mood, sleep, energy, appetite, and concentration.
- Sleep Quality Rating (SQR)Completed at baseline and after completing two-week intervention.
A brief questionnaire to rate how well you have been sleeping and whether you have experienced any sleep-related problems.